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Abstract
Background: Variations in the blood coagulation activity, determined genetically or by medication, may alter atherosclerotic
plaque progression, by influencing pleiotropic effects of coagulation proteases. Published experimental studies have
yielded contradictory findings on the role of hypercoagulability in atherogenesis. We therefore sought to address this
matter by extensively investigating the in vivo significance of genetic alterations and pharmacologic inhibition of thrombin
formation for the onset and progression of atherosclerosis, and plaque phenotype determination.
Methodology/Principal Findings: We generated transgenic atherosclerosis-prone mice with diminished coagulant or
hypercoagulable phenotype and employed two distinct models of atherosclerosis. Gene-targeted 50% reduction in
prothrombin (FII
2/WT:ApoE
2/2) was remarkably effective in limiting disease compared to control ApoE
2/2 mice, associated
with significant qualitative benefits, including diminished leukocyte infiltration, altered collagen and vascular smooth
muscle cell content. Genetically-imposed hypercoagulability in TM
Pro/Pro:ApoE
2/2 mice resulted in severe atherosclerosis,
plaque vulnerability and spontaneous atherothrombosis. Hypercoagulability was associated with a pronounced
neutrophilia, neutrophil hyper-reactivity, markedly increased oxidative stress, neutrophil intraplaque infiltration and
apoptosis. Administration of either the synthetic specific thrombin inhibitor Dabigatran etexilate, or recombinant activated
protein C (APC), counteracted the pro-inflammatory and pro-atherogenic phenotype of pro-thrombotic TM
Pro/Pro:ApoE
2/2
mice.
Conclusions/Significance: We provide new evidence highlighting the importance of neutrophils in the coagulation-
inflammation interplay during atherogenesis. Our findings reveal that thrombin-mediated proteolysis is an unexpectedly
powerful determinant of atherosclerosis in multiple distinct settings. These studies suggest that selective anticoagulants
employed to prevent thrombotic events may also be remarkably effective in clinically impeding the onset and progression
of cardiovascular disease.
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Introduction
Blood coagulation and inflammation are evolutionary coupled
host-defense mechanisms, which operate via common molecular
and cellular pathways, serve as protection against infections or
bleeding, promote wound healing and restore the integrity of
injured tissues [1–3]. Atherosclerosis is a progressive chronic
inflammatory vascular disorder, which can result in atheroscle-
rotic plaque rupture and subsequent superimposed thrombus
formation [4–6]. Besides the detrimental role of coagulation
during the onset of acute atherothrombotic complications, there
is evidence that local activation of hemostatic factors within early
human atherosclerotic lesions may also be important in
atherogenesis [7]. In addition to the overt leukocyte infiltration
into the lesions and enhanced cell death, which are considered
major markers for plaque instability, today’s concept of a
vulnerable plaque suggests that repeated plaque microruptures
and subclinical microthrombosis are critical processes to plaque
growth and subsequent atherothrombosis [8–10]. Histopatholog-
ical reports demonstrate that thrombi may exist prior to rupture
[11,12]. Numerous in vitro studies indicate that key clotting
proteases such as thrombin can also catalyze a wide range of
cellular actions related to cardiovascular function and patho-
physiology - e.g. vascular permeability, oxidative stress, migration
and proliferation of vascular smooth muscle cells, leukocyte
adhesion, chemotaxis, inflammation, and apoptosis [13]. Exper-
imental animal studies demonstrate that administration of direct
thrombin inhibitors in ApoE
2/2 mice attenuates atherosclerotic
plaque progression and promotes plaque stability of advanced
atherosclerotic lesions by reducing the levels of inflammation and
the number of macrophages infiltrating the lesions [14–16]. In
sharp contrast, there is also evidence showing that hypercoagu-
lability in ApoE
2/2 mice carrying prothrombotic mutations
promotes atherosclerotic plaque stability via thrombin-mediated
impairment of monocyte transendothelial migration [17]. In the
near future, millions of patients with arterial vascular disease will
be treated with novel, selective anticoagulant agents. Whereas
this matter remains of major scientific and clinical significance,
there is still limited understanding of the relevance of blood
coagulation in atherosclerosis in vivo [18]. In attempting to
reconcile these apparently contradictory findings, we extensively
investigated the in vivo significance of genetic alterations and
pharmacologic inhibition of thrombin formation for the onset
and progression of atherosclerosis, but also plaque phenotype
determination.
Methods
Animals
TM
Pro/Pro mice, carrying a thrombomodulin (TM) gene
mutation resulting in diminished TM-dependent generation of
activated protein C (APC) [19], and prothrombin (FII) heterozy-
gous mice with genetically imposed hypoprothrombinemia [20]
were crossed into a pure C57BL/6 background for at least 8
generations and subsequently crossbred to ApoE
2/2 mice
(Charles River, Maastricht, The Netherlands), carrying the same
background. Only female mice were used throughout the entire
study. All animal experimental protocols were carried out in
compliance with the Dutch government guidelines and were
approved by the Animal Care and Use Committee of Maastricht
University (Maastricht, The Netherlands).
Mouse Models of Atherosclerosis
In a spontaneous atherosclerosis model, female TM
Pro/
Pro:ApoE
2/2,F I I
2/WT:ApoE
2/2 (age, 8–9 weeks; n=10 per
group) and control ApoE
2/2 mice (age, 8–9 weeks; n=20)
received regular chow diet (Hope Farms, Woerden, The Nether-
lands) for 35 weeks and were then sacrificed for a detailed
analysis. In a separate experimental setup, consisting of identical
groups, carotid atherosclerotic plaques were induced via place-
ment of perivascular collars around the common carotid arteries
as described before [21]. All animals were fed on a high-fat diet
(15% cocoa butter, 1% corn oil, 0.25% cholesterol, 40.5%
sucrose, 10% cornstarch, 20% casein, free of cholate, total fat
content 16%; Hope Farms, Woerden, The Netherlands) for two
weeks before collar placement and for additional six weeks after
surgery. Diets and water were provided ad libitum throughout all
experiments.
Pharmacological Interventions
Female TM
Pro/Pro:ApoE
2/2 mice (n=10 per treatment group;
age, 8–9 weeks) fed on a standard high-fat diet (D12451; Research
Diets, NJ, USA) for 2 weeks were subsequently subjected to a
surgical implantation of non-constrictive perivascular carotid
collars and then assigned to different interventions or placebo
for a total of 6 weeks. The study design involved an intervention
arm with mice receiving standard D12451 high-fat chow
supplemented with oral Dabigatran etexilate (7.5 mg DE/gram
chow). In a second intervention arm, TM
Pro/Pro:ApoE
2/2 mice
were fed on a standard D12451 high-fat diet and received
intraperitoneal (i.p.) administration of recombinant murine APC
(rmAPC)) in bolus doses of 2.5 mg/kg/per every 5 days. Placebo-
treated mice received injection of saline and were fed on standard
D12451 high-fat chow. rmAPC was produced in the laboratory of
Dr. Charles T. Esmon (Oklahoma Medical Research Foundation
and Howard Hughes Medical Institute, Oklahoma City, Okla-
homa, USA). Both DE-supplemented high-fat and placebo chow
diets were prepared at Department of CardioMetabolic Disease
Research, Boehringer Ingelheim Pharma GmbH & Co. KG
(Biberach an der Riss, Germany).
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For an expanded Methods section, please see the online
supplement of the article (Methods S1).
Statistical Analysis
All statistics were performed using Prism, version 6.00
(GraphPad Software Inc., San Diego, CA, USA) and IBM SPSS
Statistics 20.0 (SPSS Japan Inc., an IBM company, Tokyo, Japan).
Data sets were assessed for normality using Kolmogorov-Smirnov
test or Bartlett’s test for homogeneity of variance. Data were
compared using unpaired 2-tailed t test or one-way ANOVA,
followed by Newman-Keuls posthoc test for multiple comparisons.
In case of non-normal distribution, non-parametric tests such as
Mann-Whitney or Kruskall-Wallis test with Dunn’s post hoc
analysis were used as appropriate. Data are expressed as mean 6
SD, unless otherwise stated. A 2-tailed p,0.05 was considered
statistically significant.
Results
We first generated transgenic cross breds with genetically
imposed variations in coagulation potential. Homozygous pro-
thrombin (FII) deficiency in mice results in embryonic and
neonatal lethality due to severe hemorrhagic phenotype and loss of
vascular integrity [20]. Therefore, we employed uniformly viable
FII heterozygous ApoE
2/2 mice (characterized by hypopro-
thrombinemia and diminished FVII and thrombin generation but
Figure 1. The effects of variations in coagulation potential on atherogenesis in a spontaneous atherosclerosis model at 35 weeks
on a regular chow diet. (A) Top row represents images of the aortic arch and its main branches, stained with hematoxylin and eosin (H&E), used to
analyze the extent of atherosclerotic plaque burden. To determine plaque phenotype characteristics, sections were stained against a-smooth muscle
actin (vascular smooth muscle cell content – second row), MAC-2
+ (macrophage infiltration – third row), Ly-6G (neutrophil recruitment – fourth row)
and with Sirius red (collagen – bottom row). (B) Hypocoagulability in FII
2/+:ApoE
2/2 significantly attenuated atherosclerosis plaque development
(90.6635.1*10
3 mm
2 total plaque burden) when compared to normal ApoE
2/2 mice (160.6665.9*10
3 mm
2)(n=10 per group, p=0.0084). Total
plaque area in TM
Pro/Pro:ApoE
2/2 mice was established 389.16158.4*10
3 vs. 187.0635.1*10
3 mm
2 in the corresponding control ApoE
2/2 group
(n=10 per group, p=0.0010). (C) TM
Pro/Pro:ApoE
2/2 mice atherosclerotic plaques demonstrated a significant decrease in intimal vascular smooth
muscle cell content (2.261.3% of plaque area) compared to ApoE
2/2 mice (8.762.9% of plaque area)(n=10 per group, p=0.0016). Recruitment of
macrophages within the lesions did not differ between all experimental groups (D). Neutrophil infiltration was significantly diminished in the lesions
of hypocoagulable FII
2/+:ApoE
2/2 mice (n=10 per group, p=0.0092 vs. ApoE
2/2 mice), and substantially increased in the TM
Pro/Pro:ApoE
2/2 intima
(n=10 per group, p=0.0094 vs. ApoE
2/2 mice) (E). A similar trend was observed with regard to collagen deposition within the atherosclerotic
plaques. In FII
2/+:ApoE
2/2 mice, 29.363.6% of the plaque area stained collagen-positive (n=10 per group, p=0.0002 vs. ApoE
2/2 mice). In contrast,
Sirius red staining showed only 4.163.0% positivity for collagen in the TM
Pro/Pro:ApoE
2/2 lesions (n=10 per group, p=0.0002 vs. ApoE
2/2 mice) (F).
By 35 weeks (established duration of the experiment), we recorded the following fatal events: 6 of 16 TM
Pro/Pro:ApoE
2/2, 1 of 11 FII
2/+:ApoE
2/2 and 0
of 20 ApoE
2/2 control mice. Dead mice were not included from the study analyses. The exact cause of death remained unclear. Kaplan-Meier analysis
of the survival data comparing TM
Pro/Pro:ApoE
2/2 vs. ApoE
2/2 mice, as determined by the Gehan-Breslow-Wilcoxon test, indicated that
hypercoagulability is linked to significantly higher spontaneous mortality rates (p=0.0165) (G). No significant difference was found between FII
2/+:
ApoE
2/2 and ApoE
2/2 control mice (p=0.3173) (data not shown).*p,0.05; **p,0.01; ***p,0.001. Error bars represent mean 6 SD. Arrows indicate
examples of positive staining. Abbreviations: H&E – hematoxylin and eosin; a-SMA - a-smooth muscle actin; SR – Sirius red.
doi:10.1371/journal.pone.0055784.g001
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with control, prothrombin-sufficient ApoE
2/2 mice. TM
Pro/Pro
mice carry a point mutation in the thrombomodulin (TM) gene,
which impairs TM-dependent generation of the natural anticoag-
ulant activated protein C (APC) [19]. TM
Pro/Pro:ApoE
2/2 mice
demonstrated a profound hypercoagulable state with substantially
increased plasma thrombin generation and fibrinogen levels, but
also significantly higher factor FVII, FX, and FVIII levels (Table
S1A).
Coagulation Phenotype is a Key Factor in Atherosclerotic
Plaque Growth and Phenotype Determination
We then assessed the extent, as well as the phenotype of the
atherosclerotic plaques formed in the aortic arch in experimental
cohorts of mice following 35 weeks on a regular chow diet. FII
2/+:
ApoE
2/2 mice with a genetic deficit in prothrombin exhibited
highly attenuated atherosclerotic lesion formation relative to
control ApoE
2/2 mice (Figure 1A,B). Macrophage infiltration
(MAC-2
+ cells) and a-smooth muscle actin (SMA; a-SMA
+ cells)
content were unaffected in FII
2/+:ApoE
2/2 mice lesions com-
pared to ApoE
2/2 control mice (Figure 1A,C,D). However,
hypoprothrombinemia was also linked to a significant decrease
in neutrophil recruitment (Figure 1A,E), abundant collagen
deposition (Figure 1A,F), thus showing a more fibrotic appearance,
stable plaque phenotype and decreased number of advanced
atherosclerotic lesions formed. In sharp contrast, pro-thrombotic
TM
Pro/Pro:ApoE
2/2 mice displayed severe atherosclerosis devel-
opment with remarkably increased total plaque area (Figure 1A,B).
TM
Pro/Pro:ApoE
2/2 mice showed unstable lesions (Figure 1A,B),
associated with markedly decreased a-SMA and collagen content
(Figure 1A,C,F), and significantly higher neutrophil (Ly6G
+ cells)
infiltration (Figure 1A,E). These effects were independent of plasma
lipid levels (Table S1B) and could not be attributed to an increased
uptake of modified lipoproteins by macrophages (Figure
S1A,B,C,D). Hypercoagulable TM
Pro/Pro:ApoE
2/2 mice showed
significantly increased spontaneous mortality rates, albeit that the
exact cause of death could not be pinpointed (Figure 1G).
Hence, to further verify the net effects of underlying alterations
in clotting potential on plaque phenotype, we also studied the
impact of both genetic perturbations on collar-induced carotid
artery atherosclerosis [21]. High-fat diet fed FII
2/+:ApoE
2/2
mice displayed significantly decreased plaque volume, degree of
stenosis, intima/media ratio and expansion of the arterial wall, 6
weeks after bilateral perivascular carotid collar placement
(Figure 2A,B,C,F,G). Furthermore, hypocoagulability ameliorated
plaque stability, testified by a significantly increased mean fibrous
cap thickness (Figure 2A,E). Conversely, TM
Pro/Pro:ApoE
2/2 mice
lesions were substantially larger, accompanied by significantly
increased luminal stenosis, intima/media ratio and outward
remodeling (Figure 2A,B,C,F,G). Similar to spontaneous atheroscle-
rosis, collar-induced carotid artery plaques in FII
2/+:ApoE
2/2
mice presented a stable pro-fibrotic phenotype, whereas TM
Pro/Pro:
ApoE
2/2 lesions showed pronounced features of plaque vulnera-
bility, including larger necrotic cores (Figure 2A,D), thin fibrous caps
(Figure 2A,E) and significant decrease in collagen content
(Figure 3A,B). Immunofluorescence microcopy analyses for
caspase-3 revealed enhanced apoptosis within the lesions of the
procoagulant ApoE
2/2 mice (data not shown). High plaque
vulnerability in hypercoagulable mice was also associated with a
pro-inflammatory plaque phenotype, signs of intraplaque hemor-
rhage, plaque dissection, but also spontaneous atherothrombosis
(Figure 4E, Figure 5), whereas fibrin deposits were extensively
distributed throughout ruptured TM
Pro/Pro:ApoE
2/2 lesions
(Figure 5). Intraplaque accumulation of macrophages and neutro-
phils was significantly diminished in hypocoagulable mice
(Figure 4A,B,C), indicating that deficiency in prothrombin results in
a less inflammatory plaque profile. In contrast, in TM
Pro/Pro:
ApoE
2/2 advanced carotid artery lesions were abundantly
infiltrated with neutrophils when compared to ApoE
2/2 control
mice, whereas no changes were observed in terms of macrophage
content (Figure 4A,B,C). A pronounced Ly6G
+ cell intraplaque
recruitment was also observed during early stages of atherosclerosis
in TM
Pro/Pro:ApoE
2/2 mice (Figure 4D). To provide further
understanding into how alterations in blood coagulation potential
affect the thrombogenicity of the arterial vessel wall, we pursued
complementary studies of vessel occlusion following ferric chloride
injury of healthy arteries. Times to occlusion and cessation of blood
flow as a result of thrombus formation were significantly shortened
in TM
Pro/Pro:ApoE
2/2 mice relative to control ApoE
2/2 mice,
whereas occlusion times in FII
2/+:ApoE
2/2 animals was compa-
rable to control ApoE
2/2 cohorts (Figure S2).
Hypercoagulability Triggers Initiation and Progression of
Atherosclerotic Lesions in a Neutrophil-Dependent
Manner
There was a strong positive association between the number of
circulating neutrophils in peripheral blood and the extent of
atherosclerotic plaque burden (Figure 4F). No significant correla-
tion was observed between the number of peripheral blood
monocytes and plaque size. Because of the increased neutrophil
counts observed in hypercoagulable TM
Pro/Pro:ApoE
2/2 mice
after 35 weeks on a regular chow diet (Table S1C), and the
abundant infiltration of neutrophils within vulnerable-appearing
atherosclerotic lesions (Figure 4A,C), we explored the impact of
Figure 2. Morphometrical analysis of periadventitial cuff-induced atherosclerosis in mice with genetically imposed alterations in
blood coagulation potential. (A) Representative hematoxylin and eosin (H&E)-stained sections of carotid arteries of FII
2/+:ApoE
2/2,T M
Pro/Pro:
ApoE
2/2 and control ApoE
2/2 mice (top row). Necrotic core areas of the atherosclerotic lesions were identified and quantified by using toluidine
blue (TB) staining (second and third row). (B, C) Whereas hypocoagulable mice were significantly protected against plaque progression
(26.5612.6*10
3 in FII
2/+:ApoE
2/2 vs. 69.2618.4*10
3 mm
2 in ApoE
2/2 control mice, n=10 per group, p,0.0001), pro-thrombotic mice developed
severe and occlusive atherosclerotic burden (146.4652.7*10
3 in TM
Pro/Pro:ApoE
2/2 vs. 53.9627.0*10
3 mm
2 in ApoE
2/2 control mice, n=10 per group,
p=0.0001). The degree of stenosis in TM
Pro/Pro:ApoE
2/2 reached an average of 88.668.1% (vs. 62.2616.1% in ApoE
2/2 mice, n=10 per group,
p=0.0002), whereas it was substantially lower in FII
2/+:ApoE
2/2 mice (36.8611.9% vs. 64.969.6% in ApoE
2/2 mice, n=10 per group, p,0.0001). (A,
D) Pearson’s chi-squared test (x
2) detected a significant difference in the number of advanced atherosclerotic lesions (presence of fibrous cap
atheromata [54]) formed between FII
2/+:ApoE
2/2 (4 out of 10) and TM
Pro/Pro:ApoE
2/2 mice (10 out of 10) (n=10 per group, p=0.0108). In fact, the
necrotic area within the lesions of the hypercoagulable mice was significantly increased: 56.2610.8% of the total plaque area, as compared to
29.0617.7% in the control ApoE
2/2 group (n=10 per group, p=0.0024). (E) Hypocoagulable mice showed more stable advanced lesions, as
indicated by the significantly thicker fibrous caps in comparison to ApoE
2/2 mice (n=10 per group, p=0.0081). (F) Intima/media ratio was
significantly increased in TM
Pro/Pro:ApoE
2/2 mice, whereas profoundly decreased in FII
2/+:ApoE
2/2 mice. Of note, the average outer diameter of the
common carotid artery is 0.36 mm [21], thus suggesting that TM
Pro/Pro:ApoE
2/2 atherosclerotic plaques undergo a dramatic outward remodeling as
indicated in panel (G). *p,0.05; **p,0.01; ***p,0.001. Error bars represent mean 6 SD. Arrows indicate examples of positive staining/fibrous cap
thickness. Abbreviations: H&E – hematoxylin and eosin; AL – advanced atherosclerotic lesion.
doi:10.1371/journal.pone.0055784.g002
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the context of atherosclerosis. Intravital microscopy studies
revealed that neutrophils were significantly more adherent to
atherosclerotic lesions in the common carotid artery of TM
Pro/
Pro:ApoE
2/2 than in ApoE
2/2 control mice after 6 weeks on a
high-fat diet (Figure 4G,H,I,J). These data consolidated our
histological findings (Figure 4A,C,D), suggesting that hypercoagu-
lability can promote initiation and progression of atherosclerotic
lesions in a neutrophil-dependent manner.
Hypercoagulability and Its Effects on Systemic
Inflammation and Hematopoiesis: Enhanced
Accumulation of Reactive Oxygen Species in Neutrophils
Consistent with this view, hypercoagulability promoted a
significant increase in plasma CCL2 and CXCL1 levels (Table
S2). TM
Pro/Pro:ApoE
2/2 mice showed significantly higher IL-6
plasma levels after 35 weeks on regular chow diet. Although there
were trends toward increased IL-1b, expression of other key pro-
inflammatory cytokines such as TNF-a, IFN-c, IL-5 and IL-12
were not statistically different between hypercoagulable and
control ApoE
2/2 mice, indicating that TM
Pro/Pro:ApoE
2/2 mice
Figure 3. The role of hypo- and hypercoagulability in plaque fibrosis. Picrosirius red-stained sections assessed by light (A, top row) and
polarized light (A, second row), indicate a significant decrease in the levels of collagen in TM
Pro/Pro:ApoE
2/2 carotid atherosclerotic plaques
(6.764.3% vs. 14.367.8% of total plaque area in ApoE
2/2 mice, n=10 per group, p=0.0193) (B). Hypocoagulable FII
2/+:ApoE
2/2 mice lesions
showed a pro-fibrotic appearance, testified by increased collagen deposition (24.4614.1% vs. 12.066.1% of total plaque area in ApoE
2/2 mice,
n=10 per group, p=0.0435) and a-smooth muscle actin content (25.5613.6% vs. 6.963.2% of total plaque area in ApoE
2/2 mice, n=10 per group,
p=0.0003) (B, C). *p,0.05; **p,0.01; ***p,0.001. Error bars represent mean 6 SD. Arrows indicate examples of positive staining. Abbreviations: SR –
(Picro)sirius red; a-SMA - a-smooth muscle actin.
doi:10.1371/journal.pone.0055784.g003
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S2). In addition, the higher plasma expression levels of granulo-
cyte-colony stimulating factor (G-CSF) in TM
Pro/Pro:ApoE
2/2
mice raises the possibility that the loss of TM function not only
impacts on thrombin activity but also affects granulopoiesis in the
bone marrow. However, we did not detect major changes in
hematopoiesis between hypercoagulable and control ApoE
2/2
mice after 10 weeks on regular chow diet (Figure S3), including any
preferential differentiation towards granulocytic-type colonies.
Despite a minor but significant increase in the common myeloid
progenitor (CMP) cells, lineage-negative (LK, LS, LSK),
granulocyte-macrophage progenitor (GMP) and erythroid/mega-
karyocyte progenitor (EMP) populations in TM
Pro/Pro:ApoE
2/2
mice remained unaffected (Figure S3). Nevertheless, the relative
percentage of mature granulocytes in bone marrow, as well as of
pro-atherogenic Ly6C
high monocytes [22] as measured by flow
cytometry, was significantly increased in the pro-thrombotic mice
(Figure 6A,B,C). Of interest, another consequence of chronic
hypercoagulability was enhanced accumulation of reactive oxygen
species in neutrophils and not monocytes, as assessed by DHR
fluorescence, the latter considered a measure of neutrophil
senescence (Figure 6D,E).
Figure 4. Hypercoagulability promotes neutrophil intraplaque recruitment and severe plaque phenotype. (A) Representative sections
of atherosclerotic lesions formed in the carotid arteries of TM
Pro/Pro:ApoE
2/2 and FII
2/+:ApoE
2/2 mice (incl. control ApoE
2/2 mice), stained for the
presence of macrophages (MAC-2, red color, top row) and neutrophils (Ly-6G, green color, bottom row). Arrows show examples of positive cells. DNA
is counterstained in blue. Macrophage and neutrophil infiltration were expressed as the absolute number of Mac-2
+ and Ly-6G
+ cells per plaque. (A,
B) Hypocoagulability in FII
2/+:ApoE
2/2 mice promoted an anti-inflammatory plaque profile, indicated by a significant decrease in macrophage
infiltration compared to control ApoE
2/2 mice: 2669 vs. 54615 cells per plaque (n=10 per group, p=0.0067). No difference in macrophage content
was observed between TM
Pro/Pro:ApoE
2/2 and ApoE
2/2 mice atherosclerotic plaques: 6068 vs. 58611 cells per plaque (n=10 per group, p=0.7479).
(A, C) Neutrophil accumulation was significantly increased in TM
Pro/Pro:ApoE
2/2 lesions (151648 vs. 83628 cells per plaque in ApoE
2/2 mice,
respectively; n=10 per group; p=0.0260). Interestingly, the opposite trend was observed in mice with genetically imposed hypoprothrombinemia
(51612 vs. 90624 cells per plaque in ApoE
2/2 mice, respectively; n=10 per group; p=0.0127). (D) Representative sections of early atherosclerotic
lesions in external carotid artery of a TM
Pro/Pro:ApoE
2/2 mouse (left), abundantly infiltrated by Ly-6G
+ cells (Ly-6G, red color), suggesting that
hypercoagulability triggers lesion formation in a neutrophil-dependent manner. ApoE
2/2 control mice are shown on the right hand side. (E) The
panel represents an atherosclerotic dissection with superimposed thrombus formation in a TM
Pro/Pro:ApoE
2/2 mouse at 6 weeks after carotid collar
placement. Using Perl’s Prussian blue stain (blue color), we detected free ferric ions deposited within the sites of plaque dissection, indicating the
areas of intraplaque hemorrhage. Whereas the carotid lesions in 5 out of 10 TM
Pro/Pro:ApoE
2/2 mice were associated with either rupture, dissection or
intraplaque hemorrhage, none of the control ApoE
2/2 mice plaques had any signs of severe plaque vulnerability (Pearson’s chi-squared test (x
2),
n=10 per group, p=0.0325). Statistical analysis including all experimental groups indicated that the number of circulating neutrophils in peripheral
blood was strongly correlated to the extent of atherosclerotic plaque burden (F). Using intravital microscopy, we confirmed that the relative
percentage of circulating neutrophils in TM
Pro/Pro:ApoE
2/2 mice was found significantly higher than ApoE
2/2 control mice (n=6 per group,
p=0.0107). Whereas there were no differences found in the general leukocyte rolling and arrest between TM
Pro/Pro:ApoE
2/2 and ApoE
2/2 mice after
6 weeks on a high-fat diet (Rhodamine-labeled leukocytes) (n=6 per group, p=0.2886), Ly-6G
+ neutrophils in TM
Pro/Pro:ApoE
2/2 mice were
significantly more adherent to atherosclerotic lesions in the common carotid artery than in ApoE
2/2 control mice (n=6 per group, p=0.0139). Bar
represents 100 mm. (G,H,I, J). *p,0.05; **p,0.01; ***p,0.001. Error bars represent mean 6 SD. Arrows indicate examples of positive staining. DNA
was counterstained with Hoechst-33342 (blue). Abbreviations: MF – Macrophages; IPH – intraplaque hemorrhage; TAT – thrombin-antithrombin
complex.
doi:10.1371/journal.pone.0055784.g004
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Etexilate (DE) or rmAPC Substantially Decreases Systemic
Inflammation, Aborts Atherosclerosis, Promotes Plaque
Stability And Prevents Against Atherothrombosis in
Hypercoagulable Mice
To study the role of thrombin in modulating atherogenesis
in vivo, we administered either the specific oral thrombin inhibitor
DE or a recombinant form of the natural anti-coagulant APC for 6
weeks after carotid collar placement in hypercoagulable TM
Pro/
Pro:ApoE
2/2 mice on high-fat diet. Remarkably, both interven-
tions completely rescued plaque formation (Figure 7A,B), as also
evident by the decreased degree of stenosis, intima/media ratio
and positive outward remodeling (Figure 7C,F,G). Whereas in the
placebo group 5 out of 10 animals had plaques with overt signs of
plaque vulnerability (defined as, i.e. plaque dissection, intraplaque
hemorrhage or superimposed thrombus formation), oral DE or
rmAPC treatments limited the occurrence of plaque destabiliza-
tion and atherothrombotic phenomena, and resulted in substan-
tially reduced leukocyte recruitment and enhanced plaque stability
(Figure 7A,H,I; Figure 8). In addition, both interventions led to a
pronounced decrease in thrombin generation, suggesting that even
ApoE
2/2 mice exerted a low-grade hypercoagulable state (Table
S1A, Table S3A). DE and rmAPC therapies significantly limited
systemic inflammation (Table S3C), as further exemplified by
decreased neutrophil and lymphocyte counts and cytokine and
chemokine profiles that show a shift to an anti-inflammatory state
(Table S4).
Discussion
Major Findings
These studies provide strong evidence directly documenting that
thrombin and other hemostatic system components are powerful
determinants of inflammatory vessel wall disease, and even
capable of superseding other pro-atherosclerotic insults. We here
Figure 5. Hypercoagulable TM
Pro/Pro:ApoE
2/2 mice – a new mouse model of atherosclerotic plaque vulnerability. Here we present a
new hypercoagulable atherosclerosis model, which closely mimics the composition and events leading to plaque destabilization, as normally
observed in human atherothrombosis. In a series of sections, demonstrating carotid atherosclerotic plaques, obtained from TM
Pro/Pro:ApoE
2/2 mice
at 6 weeks after collar placement on high-fat diet regimen, we show multiple signs of plaque vulnerability. (A) A non-occlusive but rapidly
progressing atherosclerotic lesion, characterized by abundant infiltration of leukocytes. (B) TM
Pro/Pro:ApoE
2/2 mice plaques tend to rupture and
dissect (upper arrow) even during the non-occlusive phase, accompanied by ‘‘silent’’ intraluminal thrombosis (lower arrows). Despite the detrimental
pathologic characteristics of those lesions, these data confirm the hypothesis that arterial thrombosis might exist long before a fatal event takes
place. This is further consolidated by the presence of so called ‘‘buried fibrous caps’’ (indicated by the arrows) in TM
Pro/Pro:ApoE
2/2 mice plaques [55],
considered a marker of healed plaque ruptures, and also observed in human atherosclerosis. Blue color denotes a massive intraplaque hemorrhage
(iron ions deposition) (C). Hypercoagulability induces a severe inflammatory and pro-necrotic intraplaque environment, leading to the formation of
enormous necrotic core, thin fibrous caps, further plaque destabilization (D) and atherothrombosis (occlusive intraluminal thrombosis/abundant
fibrin(ogen) deposition (indicated by the arrows)) (E). Thrombi undergo fibrotic organization involving vascular smooth muscle cells and fibroblasts
ingrowth, and are then partially recanalized by newly formed vessels (arrows, blue color – iron deposition/presence of erythrocytes)(F).
doi:10.1371/journal.pone.0055784.g005
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sion and qualitative properties of atherosclerotic plaques. In two
distinct experimental setups (spontaneous and collar-induced
atherosclerosis), we show that genetically-imposed 50% reduction
in prothrombin (FII
2/+) in atherosclerosis-prone ApoE
2/2 mice
remarkably diminishes lesion formation and promotes plaque
stability. In contrast, mice with genetically impaired anticoagulant
function of TM, crossed on ApoE
2/2 background, develop severe
atherosclerotic disease. We here for the first time demonstrate the
importance of neutrophils in the coagulation-inflammation inter-
play during atherogenesis. The principal finding of this study is
that hypercoagulability induces enhanced mobilization of neutro-
phils from the bone marrow into the circulation, accompanied
with neutrophil hyper-reactivity, increased oxidative stress, apop-
tosis and abundant intraplaque neutrophil infiltration, thus
promoting unstable atherosclerotic plaque phenotype and spon-
taneous atherothrombosis. Administration of either the synthetic
specific thrombin inhibitor DE or a recombinant form of the
natural anticoagulant APC, counteract the pro-inflammatory, pro-
atherogenic and pro-thrombotic phenotype of hypercoagulable
TM
Pro/Pro:ApoE
2/2 mice, resulting in plaque stability and
preventing atherothrombosis.
Coagulation and Inflammation in Atherosclerosis
Given the multifactorial nature of atherosclerosis and the well-
known capacity of coagulation proteases and their receptors
(protease-activated receptors, PARs) and substrates to control
inflammatory and reparative processes [18], one would anticipate
that hemostatic factors might contribute, at least incrementally, to
plaque development. In fact, various pro-thrombotic states have
been associated with enhanced atherosclerosis progression in mice
in vivo [23–29]. Nevertheless, the mechanisms through which
clotting contributes to atherosclerosis progression remain unclear
to date. Thrombin is a central coagulation protease, which
through the activation of PAR-1 is known to promote numerous
pro-atherogenic actions in vitro such as endothelial permeability,
migration and proliferation of VSMC, platelet activation, leuko-
cyte adhesion and recruitment, cytokine and chemokine produc-
tion, vascular calcification, angiogenesis and apoptosis [13].
Similar effects can also be triggered via both PAR-1 and PAR-2
by either TF-FVIIa complex or FXa [18]. In contrast, APC
counteracts inflammation through PAR-1 signaling at multiple
levels such as enhancing the endothelial barrier integrity,
attenuating TF and TNF-a release by monocytes, inhibiting
cytokine production, leukocyte endothelial transmigration and
NF-kB pathways [30,31].
Figure 6. Hypercoagulability induces oxidative stress in granulocytes within the bone marrow compartment. Granulocytes and
monocytes cell fractions in the bone marrow were significantly increased in TM
Pro/Pro:ApoE
2/2 as compared to ApoE
2/2 control mice after 8 weeks
on a regular chow diet (Granulocytes: 26.363.6% vs. 22.963.4%; n=12 per group, p=0.0292)(Monocytes: 12.360.6% vs. 8.860.7%; n=12 per group,
p,0.0001) (A, B). The significant increase in monocytes can be explained by the higher relative numbers of Ly6C
HIGH monocyte cells in TM
Pro/
Pro:ApoE
2/2 mice bone marrow (Ly6C
HIGH cells: 9.461.3% vs. 6.360.8%; n=12 per group, p=0.0002) (C). Using DHR123 FACS analysis, we analyzed
the amount of oxidative burst activity in granulocytes and monocytes in the bone marrow after PMA stimulation. The monocytes did not show any
differences in DHR signal and thus ROS activity, whereas in the granulocytes of the TM
Pro/Pro:ApoE
2/2 mice, a significant increase was observed in the
DHR signal when compared to ApoE
2/2 mice, indicating enhanced oxidative stress upon PMA stimulation in the TM
Pro/Pro:ApoE
2/2 granulocytes
present in the bone marrow (D, E). *p,0.05; **p,0.01; ***p,0.001. Error bars represent mean 6 SD. Abbreviations: DHR123– Dihydrorhodamine 123;
ROS – Reactive Oxygen Species; PMA - Phorbol 12-Myristate 13-Acetate.
doi:10.1371/journal.pone.0055784.g006
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due to diminished APC production in TM
Pro/Pro:ApoE
2/2 mice
may be mechanistically-coupled to the pro-atherosclerotic pheno-
type. Previous studies have indicated that hypercoagulability can
have beneficial effects on plaque stenosis during the intermediate
phases of progression by promoting positive vascular remodeling
[17]. Importantly, our data shows that plaques of prothrombotic
mice had profound composition changes, with overt features of
plaque vulnerability at later stages of disease development (at 35
weeks on regular chow diet), characterized by the presence of large
necrotic cores, thin fibrous caps, significantly increased neutrophil
intraplaque infiltration and apoptosis, decreased collagen and
VSMC content, occlusive stenosis and spontaneous atherothrom-
bosis. Despite that we show a significant association between
hypercoagulability and high rate of spontaneous mortality in
TM
Pro/Pro:ApoE
2/2 mice, further studies are needed to precisely
determine the underlying cause of this observation.
There are numerous pathways, which have been implicated to
play a role in the complex interplay between coagulation and
inflammation in various pathologic conditions [30]. Here, for the
Figure 7. Inhibition of thrombin activity by administration of direct thrombin inhibitor Dabigatran etexilate or recombinant murine
APC substantially attenuates leukocyte recruitment and prevents against severe atherosclerosis progression and atherothrom-
bosis. (A) Representative hematoxylin and eosin (H&E)-stained sections of atherosclerotic lesions formed in carotid arteries of TM
Pro/Pro:ApoE
2/2
mice, which were assigned to different intervention arms (oral Dabigatran etexilate - 7.5 mg DE/gram chow; i.p. administered bolus doses of
recombinant murine APC - 2.5 mg/kg/per every 5 days; or placebo) for a total of 6 weeks after cuff placement around the common carotid arteries
(top row). Toluidine blue (TB) stainings were used to quantify the size of necrotic core areas (second and third row). Whereas placebo treated TM
Pro/
Pro:ApoE
2/2 mice all developed advanced lesions (identified by the presence of necrotic core and fibrous cap formation), Dabigatran etexilate- (3 out
of 10, Pearson’s chi-squared test (x
2), n=10 per group, p=0.0031 vs. placebo) and rAPC-treated mice (5 out of 10, Pearson’s chi-squared test (x
2),
n=10 per group, p=0.0325 vs. placebo) had significantly reduced atheromata formed. A total of 5 out 10 animals in the placebo group showed signs
of severe plaque vulnerability, whereas none were observed in the intervention arms. Atherosclerotic plaques were further analyzed for the presence
of macrophages (MAC-2, red color, fourth row) and neutrophils (Ly-6G, green color, bottom row). Arrows show examples of positive cells.
Macrophage and neutrophil infiltration were expressed as the absolute number of Mac-2
+ and Ly-6G
+ cells per plaque. (B) Administration of either
Dabigatran etexilate or rAPC rescued the phenotype and pronouncedly reduced atherosclerotic plaque burden (Placebo: 154.3635.5*10
3 mm
2;
Dabigatran Etexilate: 3.364.4*10
3 mm
2,p ,0.001; rAPC: 7.965.5*10
3 mm
2,p ,0.01; n=10 per group). (C, F, G) These findings were further
consolidated by a significant decrease in the degree of stenosis (with ,80%), intima/media ratio and outward remodeling within the treatment arms
of the study (n=10 per group). (D, E) Except for a significant reduction of the necrotic core area in the Dabigatran etexilate-treated mice as compared
to placebo group (n=10 per group, p,0.05), no other effects were observed with regard to necrotic core formation or fibrous cap thickness. Of note,
only mice having advanced lesions were included in these analyses (Dabigatran etexilate: n=3; rAPC: n=5). (H, I) In addition, TM
Pro/Pro:ApoE
2/2 mice
treated with direct thrombin inhibitor or natural anticoagulant rAPC developed an anti-inflammatory stable plaque phenotype, associated with
substantially reduced levels of macrophage and neutrophil recruitment. *p,0.05; **p,0.01; ***p,0.001. Error bars represent mean 6 SD. Arrows
indicate examples of positive staining/fibrous cap thickness. DNA was counterstained with Hoechst-33342 (blue). Abbreviations: HFD – high-fat diet;
AL – advanced atherosclerotic lesion; MF- macrophage; rAPC – recombinant murine activated protein C.
doi:10.1371/journal.pone.0055784.g007
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(in particular thrombin) to regulate inflammation in atherosclerosis
as highlighted by the effects of direct thrombin inhibition therapy
on leukocyte counts, chemokine and cytokine levels. Neutrophils
represent another intriguing cellular interface between blood
coagulation and inflammation [3,32]. Although the importance of
neutrophils in atherosclerosis remains to be defined in detail,
several studies have highlighted their pro-atherogenic potential
and proposed role in atherosclerotic plaque destabilization [18,33–
38]. Our data demonstrate that hypercoagulability promotes
enhanced accumulation of reactive oxygen species in neutrophils
and, thus triggering enhanced neutrophil senescence. Systemic
inflammation involving activated neutrophils is associated with
unstable coronary artery disease and considered an independent
predictor for cardiovascular outcome in patients [39]. Our data
indicate increased neutrophil rolling and arrest on early carotid
atherosclerotic plaques in TM
PRO/PRO:ApoE
2/2 mice. In addi-
tion, the significantly higher neutrophil intraplaque infiltration,
consolidated by striking correlations between neutrophil counts
and the amount of plaque burden, suggest a key role for
neutrophils in this coagulation-inflammation interplay in athero-
sclerosis. The increased number of circulating pro-atherogenic
neutrophils in TM
Pro/Pro:ApoE
2/2 mice can be in part explained
by enhanced mobilization from the bone marrow as a result of
exuberant plasma G-CSF, CCL-2 and CXCL-1 expression. G-
CSF is an essential regulator of the neutrophil mobilization from
the bone marrow. Numerous experimental and human studies
have shown an association between higher G-CSF plasma levels,
neutrophil activation, endothelial dysfunction, enhanced oxidative
stress, hypercoagulability and platelet aggregation [40–42]. CCL-2
Figure 8. The effects of direct and indirect inhibition of thrombin activity on plaque fibrosis. Picrosirius red-stained sections assessed by
light (A, top row) and polarized light (A, second row), indicate no significant changes in collagen content in TM
Pro/Pro:ApoE
2/2 mice after 6-week
treatment with either Dabigatran etexilate or mouse rAPC, as compared to placebo (B). Administration of oral Dabigatran etexilate led to a significant
increase in a-smooth muscle actin intraplaque content in TM
Pro/Pro:ApoE
2/2 mice vs. placebo treatment (20.667.4% vs. 6.863.8% of total plaque
area, n=10 per group, p,0.05) (A, C). rAPC therapy did not have an effect (6.267.1% of total plaque area, n=10 per group, p.0.05) (A, C). *p,0.05;
**p,0.01; ***p,0.001. Error bars represent mean 6 SD. Arrows indicate examples of positive staining. Abbreviations: SR – (Picro)sirius red; a-SMA - a-
smooth muscle actin; HFD – high-fat diet; VSMC – vascular smooth muscle cells; rAPC – recombinant mouse activated protein C.
doi:10.1371/journal.pone.0055784.g008
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neutrophil chemoattractant activity and capacity to promote
vascular inflammation [32], but also known to be critical players in
recruitment of monocytes and neutrophils to sites of chronic
inflammation [39,43,44]. Thrombin acts as a secretagogue,
promotes endothelial dysfunction and induces the release of P-
selectin, which is stored in the Weibel-Palade bodies [45]. P-
selectin is a powerful mediator of neutrophil adhesion to the
endothelium, but also plays an important role in atherogenesis
[29,45]. Thrombin is among one of the most potent platelet
activators [18]. One may also assume that part of the pro-
atherogenic effects observed in the hypercoagulable mice can be
also mediated via platelet activation, known for their crucial role in
atherosclerosis progression [46,47]. Platelets interact with a variety
of cellular partners such as monocytes, neutrophils, endothelial
cells, endothelial progenitor cells, and others, thus induce key
inflammatory responses including leukocyte adhesion, migration,
proteolysis, thrombosis, but also facilitate the differentiation of
macrophages to foam cells [48]. Although we did neither detect
any significant correlation between the number of peripheral
monocytes and atherosclerotic plaque burden, nor changes in the
number of macrophages infiltrating the lesions in TM
PRO/PRO:
ApoE
2/2 versus control mice, this also does not rule out a role of
monocytes in atherogenesis. Neutrophils can rapidly undergo
apoptosis as a result of the enhanced oxidative stress. The
abundant number of pro-apoptotic leukocytes within the lesions of
TM
PRO/PRO:ApoE
2/2 mice can overload the phagocytic clear-
ance capacity of the macrophages, thus promoting enhanced
macrophage death and subsequent plaque necrosis [49]. In fact,
the necrotic core areas and apoptotic indices within the lesions of
hypercoagulable mice were substantially increased.
Conclusions and Potential Clinical Implications
Steadily increasing thrombin-antithrombin plasma levels, con-
sidered a sensitive marker of thrombin formation in vivo, were
independently associated with the presence and severity of
coronary atherosclerotic plaques, as defined by coronary comput-
ed tomographic angiography (CCTA) [50]. In conclusion, we here
provide substantial new evidence showing that controlling
coagulation via thrombin inhibition is a potential new therapeutic
target to treat atherosclerosis. Given the promising safety profile
and significant clinical benefits, which selective anticoagulants may
offer over traditional anticoagulant therapy [51,52], including the
reduction of risk of stroke and all-cause mortality after acute
coronary syndromes, the potential clinical importance of these
findings allows the unique opportunity to study if and how
administration of novel classes of anticoagulants modifies athero-
sclerosis phenotype in patients. Nevertheless, due to the large
heterogeneity in humans, the multifactorial nature of atheroscle-
rosis, the dual-faceted character that many coagulation factors can
exert, and their beneficial roles under normal physiological
conditions, one should consider long-term specific coagulation
inhibition with caution [53]. There is an urgent need of clinical
trials to fully assess the overall benefit and risk balance of long-
term therapy with novel oral anticoagulant agents.
Supporting Information
Figure S1 Hypercoagulability in TM
Pro/Pro:ApoE
2/2
mice does not alter lipid uptake in bone marrow-derived
macrophages (BMM). (A) There were no significant differences
found in the lipid uptake in BMM derived from TM
Pro/Pro:
ApoE
2/2 and control ApoE
2/2 mice, as determined by flow
cytometry analysis. (B, C, D) In addition, we also used high
performance thin layer chromatography to test the free cholester-
ol, cholesterol esters and triglycerides accumulation in BMM in
response to LDL and oxidized LDL loading and there were no
significant differences detected between BMM obtained from
TM
Pro/Pro:ApoE
2/2 and control ApoE
2/2 mice. Error bars
represent mean 6 SD. Abbreviations: HP-TLC - high perfor-
mance thin layer chromatography; BMM - Bone marrow-derived
macrophages; LDL – low-density lipoprotein; oxLDL – oxidized
low-density lipoprotein.
(DOC)
Figure S2 20% FeCl3-induced arterial injury in hyper-
and hypocoagulable atherosclerosis-prone mice. Time to
occlusion (TTO) and closing times (CT) were established. TTO is
defined as the time after FeCl3 application required for the blood
flow to decline to 90%, whereas CT represents the time from the
start of flow reduction to a complete occlusion of the carotid
artery. (A, B) Both TTO and CT were significantly shortened in
TM
Pro/Pro:ApoE
2/2 as compared to ApoE
2/2 control mice
(TTO: 4.460.9 vs. 14.1611.1 min., respectively; n=10 per
group, p=0.0010) (CT: 1.260.8 vs. 11.3613.0 min., respectively;
n=10 per group, p=0.0010), suggesting for a pro-thrombotic
arterial vessel wall phenotype. In contrast, hypocoagulability in
FII
2/+:ApoE
2/2 mice had no effect on thrombus formation
during FeCl3-induced arterial injury. Of note, all 10 out of 10 of
the TM
Pro/Pro:ApoE
2/2 mice formed an occlusive thrombus
(animals depicted at 30 min. represent all mice, which did not
induce occlusive thrombus formation, indicated by an arrow).
*p,0.05; **p,0.01; ***p,0.001. Dotted lines represent mean.
(DOC)
Figure S3 The effects of hypercoagulability on hemato-
poiesis. Using a CFU-C (colony forming unit in culture) assay,
we established that there were no significant differences in the
amount of total colonies produced by TM
Pro/Pro:ApoE
2/2 as
compared to ApoE
2/2 control mice after 8 weeks on a regular
chow diet (A). Furthermore, we could not find any changes in the
composition, as determined by the CFU subset analysis, indicating
that hypercoagulability does not affect hematopoiesis in the bone
marrow compartment (B). FACS analysis of the bone marrow
consolidated the results of the CFU-C assay (C, D, E). The amount
of LSK (Lin2/Sca-1+/c-Kit+) cells showed a tendency towards an
increase in the TM
Pro/Pro:ApoE
2/2 compared to ApoE
2/2
control mice (4.260.8% vs. 3.760.7%; n=12 per group,
p=0.0529) (F). The amount of CMP (common myeloid
progenitor) cells was significantly increased in the TM
Pro/Pro:
ApoE
2/2 mice compared to the controls (15.163.3% vs.
12.762.3%; n=12 per group, p=0.0402). (G). In addition,
EMP and GMP populations in the bone marrow remained
unaffected by the hypercoagulable state in TM
Pro/Pro:ApoE
2/2
mice (H, I). *p,0.05; **p,0.01; ***p,0.001. Error bars represent
mean 6 SD. Abbreviations: CFU - colony forming unit; GM -
granulocyte-macrophage progenitor; G - granulocyte progenitor;
M - macrophage progenitor; LK - cells positive for LIN
2c-Kit
+Sca-
1
2 lineage markers; LSK - cells positive for LIN
2c-Kit
+Sca-1
+
lineage markers; CMPs - common myeloid progenitors; GMP -
granulocyte/macrophage progenitors; EMP – erythroid/megakar-
yocyte progenitors.
(DOC)
Table S1 Coagulation profile (A), body weight, lipid
profile (B) and complete blood counts (C), assessed after
35 weeks on regular chow diet in FII
2/+:ApoE
2/2,
TM
Pro/Pro:ApoE
2/2 and control ApoE
2/2 mice
(n=10 per group). *p,0.05; **p,0.01; ***p,0.001. Data are
presented as mean 6 SD. Abbreviations: ETP – Endogenous
Thrombin and Atherosclerosis
PLOS ONE | www.plosone.org 12 February 2013 | Volume 8 | Issue 2 | e55784Thrombin Potential; TAT – Thrombin-Antithrombin Complex;
HDL – High-Density Lipoprotein; LDL – Low-Density Lipopro-
tein; CBC – Complete Blood Count; RBC – Red Blood Cells;
WBC – White Blood Cells; Hgb – Hemoglobin; Hct – Hematocrit.
(DOC)
Table S2 Cytokine and chemokine profile assessed
after 35 weeks on regular chow diet in FII
2/+:ApoE
2/2,
TM
Pro/Pro:ApoE
2/2 and control ApoE
2/2 mice
(n=10 per group). *p,0.05; **p,0.01; ***p,0.001. Data are
presented as mean 6 SD. Abbreviations: IL – interleukin; TNF-a
- tumor necrosis factor-alpha; IFN-c - Interferon-gamma; G-CSF -
Granulocyte colony-stimulating factor; MCP-1 - monocyte
chemotactic protein-1; MIP-1a - Macrophage inflammatory
protein-1a; MIP-1b - Macrophage inflammatory protein-1b;
RANTES - Regulated upon Activation, Normal T-cell Expressed,
and Secreted; KC - keratinocyte chemoattractant.
(DOC)
Table S3 Coagulation profile (A), lipid profile (B) and
complete blood counts (C), assessed at 6 weeks after
carotid collar placement in TM
Pro/Pro:ApoE
2/2 on high-
fat diet and treated with placebo, oral Dabigatran
etexilate or mouse recombinant APC (n=10 per group).
*p,0.05; **p,0.01; ***p,0.001 (Intervention groups compared to
placebo group). Data are presented as mean 6 SD. Abbreviations:
TAT – Thrombin-Antithrombin Complex; HDL – High-Density
Lipoprotein; LDL – Low-Density Lipoprotein; CBC – Complete
Blood Count; RBC – Red Blood Cells; WBC – White Blood Cells;
Hgb – Hemoglobin; Hct – Hematocrit; APC – Activated Protein
C.
(DOC)
Table S4 Cytokine and chemokine profile assessed at 6
weeks after carotid collar placement in TM
Pro/Pro:A-
poE
2/2
on high-fat diet and treated with placebo, oral
Dabigatran etexilate or mouse recombinant APC
(n=10 per group). *p,0.05; **p,0.01; ***p,0.001 (Interven-
tion groups compared to placebo group). Data are presented as
mean 6 SD. Abbreviations: IL – interleukin; TNF-a - tumor
necrosis factor-alpha; IFN-c - Interferon-gamma; G-CSF -
Granulocyte colony-stimulating factor; MCP-1 - monocyte
chemotactic protein-1; MIP-1a - Macrophage inflammatory
protein-1a; MIP-1b - Macrophage inflammatory protein-1b;
RANTES - Regulated upon Activation, Normal T-cell Expressed,
and Secreted; KC - keratinocyte chemoattractant; APC –
Activated Protein C.
(DOC)
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